Denali Therapeutics (DNLI) – Analysts’ Recent Ratings Updates

by · The Cerbat Gem

Several brokerages have updated their recommendations and price targets on shares of Denali Therapeutics (NASDAQ: DNLI) in the last few weeks:

  • 5/22/2026 – Denali Therapeutics had its price target lowered by Morgan Stanley from $40.00 to $35.00. They now have an “overweight” rating on the stock.
  • 5/22/2026 – Denali Therapeutics was given a new $31.00 price target by Deutsche Bank Aktiengesellschaft.
  • 5/14/2026 – Denali Therapeutics had its price target lowered by Morgan Stanley from $42.00 to $40.00. They now have an “overweight” rating on the stock.
  • 5/11/2026 – Denali Therapeutics had its “buy” rating reaffirmed by BTIG Research. They now have a $39.00 price target on the stock.
  • 5/9/2026 – Denali Therapeutics was upgraded by Wall Street Zen from “strong sell” to “sell”.
  • 5/8/2026 – Denali Therapeutics had its price target lowered by Wedbush from $25.00 to $23.00. They now have an “outperform” rating on the stock.
  • 4/25/2026 – Denali Therapeutics was downgraded by Wall Street Zen from “sell” to “strong sell”.
  • 4/22/2026 – Denali Therapeutics had its price target lowered by Leerink Partners from $40.00 to $35.00. They now have an “outperform” rating on the stock.
  • 4/20/2026 – Denali Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
  • 4/7/2026 – Denali Therapeutics had its price target raised by Robert W. Baird from $32.00 to $34.00. They now have an “outperform” rating on the stock.

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.

See Also